Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 22 September 2026 regarding the successful private placement of 1,531,000 new shares (the "Private Placement"), divided on a first tranche of 990,689 shares ("Tranche 1") and a second tranche of 540,311 shares ("Tranche 2"), and the allocation of 119,000 new shares in a retail offering carried out via Nordnet (the "Retail Offering").
The share capital increase pertaining to the issuance of the in total 1,650,000 new shares in the Private Placement and Retail Offering (the "New Shares") has now been registered with the Norwegian Register of Business Enterprises. The Company's new share capital is NOK 1,532,103 divided on 6,128,412 shares, each with a par value of NOK 0.25.
895,681 of the New Shares will be issued on the Company's existing ISIN and will hence be admitted to trading as soon as they have been issued in the VPS. The remaining 754,319 New Shares will be issued on a separate, temporary ISIN pending approval by the Norwegian Financial Supervisory Authority (Norwegian:
Finanstilsynet) of a listing prospectus. The New Shares delivered on the separate, temporary ISIN will thus not be listed or tradeable on Euronext Oslo Børs until such listing prospectus has been approved and published, expected during Q4 2026.
For further information, please contact:
Oystein Soug, Chief Executive Officer